Ladies and gentlemen, thank you for standing by, and welcome to the Zymergen business update conference call. At this time, all participants are on a listen only mode. I will now turn the conference to your host, Ms. Carrie Mendivil, with Investor Relations. Please go ahead. Thank you. Earlier today, Zymergen issued a joint press release with Ginkgo Bioworks announcing a definitive merger agreement for Ginkgo to acquire Zymergen. Joining me today to discuss this announcement, as well as other organizational updates, is Jay Flatley, Acting Chief Executive Officer of Zymergen. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Ginkgo Bioworks and Zymergen issued today. For a more complete list and description, please see the Risk Factors section of each company's latest 10-K and other filings with the Securities and Exchange Commission, including the 10-Q for the first quarter of 2022. Except as required by law, Zymergen disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast July 25, 2022. We do not plan for a Q&A as part of this call. With that, I'd like to turn the call over to Jay. Thanks, Carrie, and good afternoon, everyone. We appreciate you joining us on relatively short notice. As you saw this morning, we announced the definitive agreement whereby Ginkgo Bioworks will acquire Zymergen in a stock for stock transaction. Zymergen shareholders will receive 0.9179 Ginkgo shares for each Zymergen share, representing 5.25% pro forma ownership of the combined company upon completion of the transaction. Based on Ginkgo's closing stock price on July 22, 2022, this deal values Zymergen at approximately $2.68 per share or a total transaction value of $300 million. This represents a 34% premium to Zymergen's closing price on July 22, 2022, and a 71% premium to the 30 calendar day volume weighted average price. This transaction pairs two highly complementary synthetic biology organizations that share a common vision that biology can transform a wide range of industries, including manufacturing, agriculture, and medicine. Both companies share the goal to build organizations and tools that enable this vision to become a reality. We expect the transaction to close by Q1 2023. It is subject to typical closing conditions, including approval of holders of the majority of Zymergen's outstanding common stock, expiration or termination of customary regulatory waiting periods, and Ginkgo registering the shares to be issued in the merger with the SEC, among other things. In connection with the signing of the merger agreement, SoftBank, DCVC and True Ventures, who together hold approximately 40% of Zymergen's outstanding common stock, have entered into voting agreements with Ginkgo, agreeing to vote in favor of the transaction. At Zymergen, our team has built an innovative world-class technology platform that complements Ginkgo's cell programming capabilities. We are very excited about the opportunities that will be created by combining our technologies to accelerate Ginkgo's platform development to better serve customers and achieve our shared vision of sustainability and a world built on biology. As Jason Kelly, Ginkgo's CEO and Co-founder, shared on their call this morning, Ginkgo plans to integrate our core automation and software technologies for scaling strain engineering capacity into its foundry, including our machine learning and data science tools for exploring known and unknown genetic design space. This allows them to bring benefits of Zymergen's technology and extensive IP portfolio to more customers across multiple industries at an accelerated pace. Ginkgo will remain a horizontal platform serving all industries rather than producing its own products. For some time, we have been evaluating the potential of splitting the company into multiple independent businesses. We are very pleased that Ginkgo is supportive of our efforts to continue to explore these strategic options, particularly for two slimmed down companies in advanced materials and drug discovery. These options could include independent private company spin-outs or combinations with existing organizations, and if successful, could result in cost savings with the potential to benefit all stakeholders. As part of our continued efforts to execute on our strategic plan, including refocusing the business and managing costs to conserve cash resources, we are reducing our workforce, which will occur in multiple phases beginning tomorrow. Just a couple of quick updates on those businesses. In advanced materials, we have continued to make progress in our nitrogen fixation, water repellency, and 3D printing programs. However, we've reached a mutual decision with Sumitomo to pause development work on our Z1 polymer as we've not received a sufficiently strong demand signal from the market to continue this work in the near term. Our partnership with Sumitomo continues, and we are exploring additional opportunities for the novel biomolecules we have created and potentially expanding our partnership to develop new chemical building blocks. For our mRNA enzyme program, we have achieved the target technical specifications and productivity and are in the optimization and scale-up phases of the project. As such, we are reviewing various options, including licensing, to commercialize ZCE and 2'-OMT. Zymergen's drug discovery business continues to develop. Our existing collaborations are milestones. Discussions with potential additional partners are progressing, and we are exploring collaborations with multiple leading pharma. In addition to discussions related to genetically encoded small molecules, we've had early discussions about how to leverage our metagenomic libraries for applications related to gene editing. Lastly, our pipeline of full programs for synthetic lethal targets continues to make progress. To close, I'd like to reiterate my excitement about the merger of Zymergen and Ginkgo, integrating both companies' technologies to better serve customers, promoting Zymergen's public benefit purpose, and achieving our shared vision of sustainability in a world built on biology. Our board carefully and thoroughly reviewed the strategic and financial benefits of this opportunity and has unanimously agreed that this transaction represents a compelling opportunity for all of our stakeholders. We believe it maximizes value and will allow for continued potential upside through ownership of the combined company and the potential spin-outs. The market remains hungry for a new generation of technology that will transform the way materials are manufactured. We are confident that as part of Ginkgo, Zymergen will be a significant contributor to that future. Thank you very much. Thank you. Ladies and gentlemen, this does conclude today's conference. You may now disconnect. Have a great day.